Skip to content
Screener

Financing Cash Flow at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$412.29M-33,163%
Biogen logo
BiogenBIIB
$1.3B+11,177%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$10.49M-34.2%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$394.19M+13,285%
uniQure logo
uniQureQURE
$249.12M+566,073%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$19.93M+86,570%

Other financials

Income statement

See full
Revenue--100%
Operating income-$47.3M-77.0%
Net income-$46.6M-73.5%
EPS (diluted)-$0.13-44.4%

Balance sheet

See full
Cash & equivalents$455.4M+45.6%
Total debt$56.7M-5.1%
Total equity$387.3M+55.7%
Total assets$470.4M+41.1%

Cash flow

See full
Operating cash flow-$40.4M-100%
CapEx$24.0K-93.7%
Free cash flow-$40.4M-100%

Valuation

See full
Market cap$1.83B+154%
Enterprise value$1.43B+205%
P/S333.7×+245×

Profitability

See full
Operating margin-2,792.3%-9,679pp
Net margin-2,728%-9,858pp
FCF margin-2,417%-8,925pp

Returns & leverage

See full
Return on equity-47.1%-4.0pp
Debt / equity0.1×-0.1×
Current ratio17.8×+5.3×

Where this comes from

Reported directly by Taysha Gene Therapies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:07 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-344610
Line itemFor the Six Months Ended June 30, 2026For the Six Months Ended June 30, 2025
Proceeds from common stock issuances under ESPP17675
Proceeds from stock option exercises957
Other9438
Net cash provided by financing activities217,366216,236
Net increase in cash, cash equivalents and restricted cash133,040173,725
Cash, cash equivalents and restricted cash at the beginning of the period322,531141,636
Cash, cash equivalents and restricted cash at the end of the period$455,571$315,361
Cash and cash equivalents455,407312,761

Item 1. Financial Statements.

FAQ

What is Taysha Gene Therapies, Inc.'s financing cash flow?
Taysha Gene Therapies, Inc. (TSHA) reported financing cash flow of $216.66M in Q2 2026.
How has Taysha Gene Therapies, Inc.'s financing cash flow changed year-over-year?
Taysha Gene Therapies, Inc.'s financing cash flow increased by 0.2% year-over-year, from $216.29M to $216.66M.
What is the long-term trend for Taysha Gene Therapies, Inc.'s financing cash flow?
Over 3 years (2022 to 2025), Taysha Gene Therapies, Inc.'s financing cash flow has grown at a 73.9% compound annual growth rate (CAGR), from $52.2M to $274.59M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Taysha Gene Therapies, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude